PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN  by Chao, TY et al.
PCN16
COST-EFFECTIVENESS ANALYSIS OF ADJUVANT
TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST
CANCER INTAIWAN
Chao TY1, Chen SC2, Chang KJ3, Chang HK4, Chen DR5, Hou MF6,
Hsieh RK7, Huang WT8,Tseng LM9,Wang HC10,Yang L11,
Cirrincione A12
1Tri-Service General Hospital,Taipei,Taiwan, 2Chang Guang Memorial
Hospital,Taipei Branch,Taipei,Taiwan, 3National Taiwan University
Hospital,Taipei,Taiwan, 4Chang Guang Memorial Hospital, Linkou
Branch, Linkou,Taiwan, 5Changhua Christian Hospital, Changhua,
Taiwan, 6Kaohsiung Medical University Hospital, Kaohsiung,Taiwan,
7Mackay Memorial Hospital,Taipei,Taiwan, 8Chimei Medical Center,
Tainan,Taiwan, 9Taipei Veterans General Hospital,Taipei,Taiwan,
10China Medical University Hospital,Taichung,Taiwan, 11Roche
Products Ltd,Taipei,Taiwan, 12F.Hoffmann-La Roche Ltd, Basel,
Switzerland
OBJECTIVES: Results from the HERA, NSABP B-31, and
NCCTG N9831 trails demonstrated a reduction in risk of recur-
rence by approximately 50% with the addition of trastuzumab to
standard adjuvant therapy in early breast cancer (EBC). The
objective of this cost-effectiveness analysis (CEA) is to evaluate
the long term clinical outcomes and economic impact of one year
adjuvant trastuzumab compared to no trastuzumab in addition
to standard adjuvant therapy for patients with HER2-positive
EBC in Taiwan from the payer’s [Bureau of National Health
Insurance (BNHI)] perspective. METHODS: A ﬁve-state Markov
model was developed to estimate the incremental cost and long-
term health outcomes in terms of quality-adjusted life years
(QALYs) of EBC over a patient’s lifetime. Clinical outcomes and
disease transition probabilities were derived from the HERA
trial. Direct medical costs associated with drugs, trastuzumab
administration, and HER2 testing were based on Taiwan’s
National Health Insurance fee schedule 2007. Medical resource
utilizations associated with disease free survival (DFS), recur-
rence, metastasis, and cardiac side effects were estimated by
an expert panel survey conducted among ten oncologists.
Population-based utilities were applied to the main health states
in the Markov model, while disutilities of cardiac events were
obtained from published literature. Beneﬁts and future costs were
discounted at annual rate of 3.5%. One-way sensitivity analyses
were performed on key model parameters. RESULTS: Compared
to standard adjuvant therapy alone, adding trastuzumab to stan-
dard treatment increased drugs costs and DFS, however, the
incremental costs were offset by reduced costs of recurrence and
metastasis. Over a lifetime, one year adjuvant trastuzumab
yielded an incremental cost-effectiveness ratio (ICER) of
NTD$152,620 (€3,451) per QALY. Adjuvant trastuzumab
remained cost-effective under sensitivity testing. CONCLU-
SION: From the perspective of Taiwan BNHI, this CEA demon-
strates that one year adjuvant trastuzumab offers health beneﬁts
at a favorable ICER in patients with HER2-positive EBC.
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OBJECTIVES: In 2007 trastuzumab (T) received regulatory
approval in Brazil for 1 year treatment of HER2-positive patients
with early breast cancer (eBC) in addition to standard chemo-
therapy. The objective of this analysis is to estimate cost-
effectiveness of T in eBC from the private third-party payer
perspective. METHODS: A Markov state transition model was
designed to capture the natural history and course of disease for
early stage breast cancer patients, and to simulate cost and
disease progression over a life time perspective. Disease transi-
tion probabilities and clinical outcomes were derived from the
HERA trial. Direct costs were considered to estimate the incre-
mental cost-effectiveness ratio using both quality-adjusted life
years (QALYs) and life years gained (LYGs). A local Delphi panel
was conducted to reﬂect local clinical practice and assess medical
care utilization (for disease-free survival, loco-regional recur-
rence, metastasis, and cardiac side effects). Unit costs were based
on published sources (drugs and materials national prices list and
medical society fees list). Utilities and disutilities were obtained
from published literature. The discount rate of 3% was adopted
for both health outcomes and costs. Both one-way and probabi-
listic sensitivity analysis were performed to verify the robustness
of the results. RESULTS: T treatment costs were higher in com-
parison with standard treatment, showing higher acquisition
drug costs (R$ 190,554) and administration costs (R$ 2,160).
On the other hand, cost-offsets for R$ 168,331 were estimated
due to the reduction of the metastatic and recurrence cases. T
treatment showed an increase in LYG (1.74) and QALYs (1.80).
The estimated ICER was R$ 22,587 per QALY gained. CON-
CLUSION: From a third-party payer, this analysis suggests that
trastuzumab treatment for HER-2 positive patients with early
breast cancer is a cost-effective alternative in Brazil.
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OBJECTIVES: In an ongoing, phase III trial, sunitinib was sig-
niﬁcantly superior to IFN-a in ﬁrst-line therapy of mRCC;
(median progression-free survival [PFS] = 11 months [95% CI:
10–12] vs. 4 months [95% CI: 4–6]; P < 0.000001). This study
investigated the cost-effectiveness of sunitinib vs. IFN-a in this
setting from a US third-party payer perspective. METHODS: A
Markov model with a 10-year time horizon projected survival
and costs in 6-week cycles based on extrapolated trial survival
data. First- and second-line treatment and palliative care were
examined. The endpoints used to value model outcomes were
PFS; overall survival (OS); quality of life; adverse events (AEs)
and related dose reductions or cycle interruptions. Progression-
free months (PFM), life-years (LY) gained and quality adjusted
life-years (QALYs) gained were used to assess treatment efﬁcacy.
Costs incurred included those associated with physician visits,
hospitalisation, tests, scans, drugs, monitoring and treatment of
AEs. Costs (adjusted to 2006 US dollars) and survival beneﬁts
were discounted annually at 5% and sensitivity analyses (sce-
nario and probabilistic) were conducted. Results were presented
as incremental cost-effectiveness ratios (ICERs) and incremental
cost-utility ratios (ICURs). RESULTS: Longer projected PFS and
OS were obtained for sunitinib than for IFN-a. The ICERs of
sunitinib vs. IFN-a over 10-years were $1,551/PFM, $67,215/LY
and $52,593/QALY gained. Based on the probabilistic sensitivity
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